Published in Cardiovasc Res on September 10, 2014
New approaches to establish genetic causality. Trends Cardiovasc Med (2015) 1.41
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Prolonged action potentials in HCM-derived iPSC--biology or artefact? Cardiovasc Res (2015) 1.06
Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta (2015) 0.92
Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells. J Mol Cell Cardiol (2015) 0.91
Identification and Functional Characterization of a Novel CACNA1C-Mediated Cardiac Disorder Characterized by Prolonged QT Intervals With Hypertrophic Cardiomyopathy, Congenital Heart Defects, and Sudden Cardiac Death. Circ Arrhythm Electrophysiol (2015) 0.89
Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. Cell Rep (2015) 0.89
Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. Dis Model Mech (2015) 0.88
Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. Cardiovasc Res (2015) 0.85
Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget (2016) 0.82
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. J Cardiovasc Transl Res (2016) 0.79
Liensinine- and Neferine-Induced Cardiotoxicity in Primary Neonatal Rat Cardiomyocytes and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int J Mol Sci (2016) 0.78
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model for Heart Development and Congenital Heart Disease. Stem Cell Rev (2015) 0.76
Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol (2016) 0.76
Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. Front Physiol (2016) 0.76
Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy. Stem Cells Int (2015) 0.76
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol Life Sci (2017) 0.75
Generation of electrophysiologically functional cardiomyocytes from mouse induced pluripotent stem cells. Stem Cell Res (2016) 0.75
Novel Analysis Software for Detecting and Classifying Ca2+ Transient Abnormalities in Stem Cell-Derived Cardiomyocytes. PLoS One (2015) 0.75
G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling. Front Cell Dev Biol (2015) 0.75
Patient-Specific Induced Pluripotent Stem Cell Models: Generation and Characterization of Cardiac Cells. Methods Mol Biol (2016) 0.75
Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? J Neuromuscul Dis (2016) 0.75
Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants. Front Physiol (2016) 0.75
Reconciling computer models and stem cell models of human cardiac repolarization: reply. Cardiovasc Res (2015) 0.75
Biology of the cardiac myocyte in heart disease. Mol Biol Cell (2016) 0.75
Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia. J Atr Fibrillation (2016) 0.75
Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. Dis Model Mech (2017) 0.75
Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies. Curr Cardiol Rep (2017) 0.75
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc (2012) 35.75
RNA-guided genetic silencing systems in bacteria and archaea. Nature (2012) 17.12
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998) 13.56
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature (2008) 10.27
Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol (2000) 9.88
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Hypertrophic cardiomyopathy: a systematic review. JAMA (2002) 9.15
Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol (2008) 6.19
Modelling the long QT syndrome with induced pluripotent stem cells. Nature (2011) 5.68
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci U S A (2007) 3.90
Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res (1989) 3.57
Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci U S A (2006) 3.54
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res (1999) 3.43
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev Cell (2005) 2.93
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
Molecular mechanisms of inherited cardiomyopathies. Physiol Rev (2002) 2.32
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol (2012) 2.25
Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res (1995) 1.94
Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci U S A (2000) 1.82
Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res (2012) 1.69
Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol (2011) 1.59
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res (2003) 1.42
WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res (2010) 1.34
Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest (1996) 1.18
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol (2010) 1.14
FGF induces hypertrophy and angiogenesis in hibernating myocardium. Circ Res (2005) 1.11
Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ Res (1989) 1.10
SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. Neurosci Lett (2006) 1.09
High-purity enrichment of functional cardiovascular cells from human iPS cells. Cardiovasc Res (2012) 1.07
Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation (2001) 1.06
E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer (2003) 1.01
Regulation of proliferation of the fetal myocardium. Dev Dyn (2000) 0.95
[Beta-myosin heavy-chain gene mutations in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol (2006) 0.94
E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway. Acta Pharmacol Sin (2012) 0.89
CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian Pac J Cancer Prev (2013) 0.87
The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol (2011) 0.85
Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase protein expression in compensated primary and secondary human cardiac hypertrophy. J Mol Cell Cardiol (1999) 0.79
Reconciling computer models and stem cell models of human cardiac repolarization: reply. Cardiovasc Res (2015) 0.75